Patents Assigned to The United States of Americans represented by the Secretary, Department of Health and Human Services
-
Patent number: 11746335Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: GrantFiled: April 19, 2022Date of Patent: September 5, 2023Assignee: The Government of the United States of American, as represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
-
Patent number: 11629334Abstract: Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.Type: GrantFiled: December 11, 2019Date of Patent: April 18, 2023Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Alena Gros, Steven A. Rosenberg
-
Patent number: 11471460Abstract: Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R1, R2, and R3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.Type: GrantFiled: May 26, 2020Date of Patent: October 18, 2022Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Melvin L. DePamphilis, Gaurav Sharma, Juan Jose Marugan, Marc Ferrer, Ajit Roy
-
Patent number: 11384139Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.Type: GrantFiled: July 27, 2018Date of Patent: July 12, 2022Assignees: The United States of Americans represented by the Secretary, Department of Health and Human Services, University of Virginia Patent FoundationInventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
-
Patent number: 11359204Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: December 10, 2020Date of Patent: June 14, 2022Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 11352410Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for Kita-Kyushu Lung Cancer Antigen 152-60 (KK-LC-152-60). Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: April 17, 2017Date of Patent: June 7, 2022Assignee: The United States of American, as represented by the Secretary, Department of Health and Human ServiceInventors: Sanja Stevanovic, Christian S. Hinrichs
-
Patent number: 11338032Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.Type: GrantFiled: July 12, 2021Date of Patent: May 24, 2022Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Christian S. Hinrichs, Steven A. Rosenberg
-
Patent number: 11311613Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.Type: GrantFiled: November 6, 2017Date of Patent: April 26, 2022Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang
-
Patent number: 11241436Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.Type: GrantFiled: January 25, 2018Date of Patent: February 8, 2022Assignees: Northwestern University, The United States of Americans represented by the Secretary, Department of Health and Human Services, University of KansasInventors: Congcong He, Sui Huang, Chen Wang, Altea Rocchi, Juan Jose Marugan, Marc Ferrer, Samarjit Patnaik, Yuchi Chen, Kevin Frankowski, Frank J. Schoenen
-
Patent number: 11192903Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.Type: GrantFiled: December 20, 2019Date of Patent: December 7, 2021Assignee: The United States of Americans, as represented by the Secretary, Department of Health and Human ServicesInventors: Noriko Sato, Haitao Wu, Gary L. Griffiths, Peter L. Choyke
-
Patent number: 11077182Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.Type: GrantFiled: December 7, 2020Date of Patent: August 3, 2021Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Christian S. Hinrichs, Steven A. Rosenberg
-
Patent number: 10900042Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.Type: GrantFiled: November 14, 2019Date of Patent: January 26, 2021Assignee: The United States of Americans, as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 10864252Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.Type: GrantFiled: October 29, 2018Date of Patent: December 15, 2020Assignee: The United States of Americans represented by the Secretary, Department of Health and Human ServicesInventors: Richard A. Morgan, Nachimuthu Chinnasamy, Steven A. Rosenberg
-
Patent number: 10047147Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: GrantFiled: August 4, 2014Date of Patent: August 14, 2018Assignee: The United States of American, as represented by the Secretary, Department of Health and Human ServicesInventors: Mark Connors, Jinghe Huang, Leo Laub, John Mascola, Nancy Longo, Nicole Doria-Rose